rs11132911 - LINC02174
Magnitude 4.5 · 1 study on file
Reported associations
-
A molecular pathway analysis informs the genetic risk for arrhythmias during antipsychotic treatment. - International clinical psychopharmacology (2018) · Drago A, Kure Fischer E · PubMed 29064910
Arrhythmias are a frequent and potentially fatal side effect of antipsychotic treatment. Strict ECG monitoring and clinical interviews are the standards used to prevent arrhythmias. A biologic predictive tool is missing. The identification of a genetic makeup at risk of antipsychotic-induced arrhythmias is the aim of the present investigation. The aim of this study was to identify a molecular pathway enriched in single nucleotide polymorphisms associated with antipsychotic-induced QTc modifications. In total, 661 schizophrenic individuals from the CATIE study, M=486 (73.52%), mean age=40.92±11.02, were included. QTc variation was measured as a phase-specific change-created variable. A nested mixed regression for a repeated-measures model served in R for the analysis of the clinical and tr
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
antipsychotic choice and QTc risk Moderate
This variant is associated with increased QTc prolongation in response to antipsychotics, increasing arrhythmia risk.
Review with prescriber before starting antipsychotics; request QTc monitoring plan.
Screening
-
baseline ECG and QTc if taking antipsychotics Moderate
Carriers show increased antipsychotic-induced QTc prolongation; ECG detects arrhythmia risk early.
Get baseline ECG before antipsychotic initiation; repeat per prescriber recommendation.